Making cell-free DNA testing accessible to all healthcare providers
FDA Breakthrough Device Designation Marks Major Milestone for Gene Solutions’ SPOT-MAS 10 Multi-Cancer Screening Test
Gene Solutions divider

FDA Breakthrough Device Designation Marks Major Milestone for Gene Solutions’ SPOT-MAS 10 Multi-Cancer Screening Test

Key finding:

SINGAPORE, May 27, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company advancing accessible genomic solutions for cancer detection and precision oncology, today announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation to SPOT-MAS 10, its multi-omic blood test designed to detect cancer-associated signals.

Authors:

GENE SOLUTIONS SGP PTE. LTD.
Publisher:PR Newswire
Publication date:28 May 2026
Advancing Precision Oncology in Taiwan
Gene Solutions divider

Gene Solutions Showcases AI-Powered Multi-Omics Liquid Biopsy Innovations at TJCC 2026: Advancing Precision Oncology in Taiwan

Key finding:

TAIPEI, May 22, 2026 /PRNewswire/ — Gene Solutions, an innovative global biotechnology company advancing AI-powered multi-omics solutions for cancer detection and precision oncology, participated in the 30th Taiwan Joint Cancer Conference (TJCC 2026), marking its first major oncology conference presence in Taiwan.

Authors:

Gene Solutions Genomics Pte Ltd
Publisher:PR Newswire
Publication date:22 May 2026
Gene Solutions Announces Strategic Entry into Türkiye with Robust Real-World Evidence at the 2nd International Hereditary Cancers Congress 2026
Gene Solutions divider
A Vietnamese longitudinal prospective cohort study (K-DETEK)
Gene Solutions divider

Comprehensive validation of a cell-free DNA-based assay for multi-cancer detection: A Vietnamese longitudinal prospective cohort study (K-DETEK)

Authors:

Le Son Tran¹˒², Dang Luu-Hong Nguyen¹˒², Hanh Thi-Hue Nguyen¹˒², et al.
Publisher:ASCO Breakthrough
Publication date:09 August 2024
This publication supports for the following genetic testing:
Making cell-free DNA testing accessible to all healthcare providers
triSure NIPT Debuts in Taiwan, Expanding Non-Invasive Prenatal Screening Beyond Aneuploidy
Gene Solutions divider

triSure NIPT Debuts in Taiwan, Expanding Non-Invasive Prenatal Screening Beyond Aneuploidy

Key finding:

TAIPEI, April 14, 2026 /PRNewswire/ — At the prestigious Taiwan Association of Obstetrics and Gynecology (TAOG) 2026 Annual Meeting—the nation’s largest obstetrics and gynecology society established in 1961— Gene Solutions Taiwan officially introduced triSure, a revolutionary non-invasive prenatal screening technology.

Authors:

Gene Solutions Genomics Pte Ltd
Publisher:PR Newswire
Publication date:14 April 2026
Genomics & AI Blood Test Detects Cancer Before Symptoms Appear in India
Gene Solutions divider
Gene Solutions and Pangea Laboratory Establish Strategic Collaboration to Validate Laboratory Developed ctDNA Tests for Precision Screening and Cancer Care in the U.S.
Gene Solutions divider

Gene Solutions and Pangea Laboratory Establish Strategic Collaboration to Validate Laboratory Developed ctDNA Tests for Precision Screening and Cancer Care in the U.S.

Key finding:

IRVINE, Calif., Jan. 21, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company, and Pangea Laboratory, a CLIA-certified, CAP-accredited Next Generation Sequencing (NGS) leader in validation platforms for Laboratory Developed Tests (LDTs), announced a strategic collaboration to advance U.S. verification and clinical validation of liquid biopsy assays designed for cancer detection, profiling, and monitoring.

Authors:

Gene Solutions Genomics Pte Ltd
Publisher:PR Newswire
Publication date:21 January 2026
Gene Solutions Concludes Successful ESMO Asia Congress 2025 with AI-Powered Multi-Omics Liquid Biopsy Symposium and Two Best Poster Awards
Gene Solutions divider

Gene Solutions Concludes Successful ESMO Asia Congress 2025 with AI-Powered Multi-Omics Liquid Biopsy Symposium and Two Best Poster Awards

Key finding:

SINGAPORE, Dec. 20, 2025 /PRNewswire/ — Gene Solutions, a pioneering genetic testing company, announced key achievements at the European Society for Medical Oncology (ESMO) Asia Congress 2025—held in Singapore on December 5–7. Highlights included a full-house symposium, seven scientific abstracts with two earning Best Poster designations, and meaningful engagement with thousands of oncologists from across the Asia-Pacific region at the company’s exhibition booth.

Authors:

Gene Solutions Genomics Pte Ltd
Publisher:PR Newswire
Publication date:20 December 2025
Tumor-naïve multimodal profiling of circulating tumor DNA to detect minimal residual disease in solid tumors
Gene Solutions divider

Tumor-naïve multimodal profiling of circulating tumor DNA to detect minimal residual disease in solid tumors

Key finding:

The tumor-naïve method could be a reliable alternative to monitor ctDNA when obtaining high-quality tissue samples is challenging. The performance of this method was better in high ctDNA-shedding cancer or at the metastatic stage.

Authors:

Tu Nguyen, Van-Anh Nguyen Hoang, Trong Hieu Nguyen, Trung Hieu Tran, Ngoc Nguyen, Tho Thi Le Vo, Duy Sinh Nguyen, Hoa Giang, Hoai-Nghia Nguyen, and Lan N. Tu
Publisher:Therapeutic Advances in Medical Oncology
Publication date:18 November 2025
This publication supports for the following genetic testing:
Making cell-free DNA testing accessible to all healthcare providers
Analytical Validation and Clinical Insights
Gene Solutions divider

Tumor Genomic and Transcriptomic Analysis Integrated With Liquid Biopsy ctDNA Monitoring: Analytical Validation and Clinical Insights

Key finding:

Comprehensive genomic profiling (CGP) is a time- and tissue- efficient method to help guide precision oncology. To enhance the clinical utility of CGP, we investigated the performance of a novel strategy integrating tumor DNA and mRNA profiling, together with liquid biopsy ctDNA monitoring. Comprehensive genomic and transcriptomic profiling could reliably unveil genetic details not provided by DNA-only CGP. The integration of ctDNA detection further helped detect tumor-agnostic mutations and monitor treatment response.

Authors:

Nam H. B. Tran, Thien-Phuc Hoang Nguyen, Vinh Quang Bui, Vu Thuong Le, Trong Khoa Mai, Van-Anh Nguyen Hoang, Tien Anh Nguyen, Minh-Duc Nguyen, Ha-Hieu Pham, Tho Thi Le Vo, My T. T. Ngo, Du Quyen Nguyen, Duy Sinh Nguyen, Hoai-Nghia Nguyen, Minh-Duy Phan, Hoa Giang, Lan N. Tu
Publisher:Cancer Medicine
Publication date:08 December 2025
This publication supports for the following genetic testing:
Making cell-free DNA testing accessible to all healthcare providers
AI-Powered Multi-Cancer Early Detection Ushers in a New Era of Precision Medicine
Gene Solutions divider

SPOT-MAS Launches in Taiwan: AI-Powered Multi-Cancer Early Detection Ushers in a New Era of Precision Medicine

Key finding:

TAIPEI, Nov. 28, 2025 /PRNewswire/ — Precision medicine is entering a new era, driven by breakthroughs in genetic technology and Artificial Intelligence (AI). Multi-Cancer Early Detection (MCED) has become a global trend, and Taiwan joins this movement with the introduction of SPOT-MAS – an advanced screening solution developed by Gene Solutions, a global leader in precision oncology and genomics, in collaboration with local partner Gene Health.

Authors:

Gene Solutions Genomics Pte Ltd
Publisher:PR Newswire
Publication date:28 November 2025
APAC Precision Oncology Conference Outlines the Future of Early Detection and Personalized Treatment
Gene Solutions divider

AI and Multi-omics are Transforming Cancer Care: APAC Precision Oncology Conference Outlines the Future of Early Detection and Personalized Treatment

Key finding:

HONG KONG, Nov. 17, 2025 /PRNewswire/ — The APAC Precision Oncology Conference 2025, themed Artificial Intelligence (AI) & Multi-omics in Cancer Management, convened in Hong Kong on November 1, marking Lung Cancer Awareness Month with a clear message: AI and multi-omics are no longer theoretical – they are driving real-world advancements in cancer care across the Asia-Pacific (APAC) region.

Authors:

Gene Solutions Genomics Pte Ltd
Publisher:PR Newswire
Publication date:01 November 2025
1
2
3
4
5
…
8
Discover More